New Data Shows Heart Failure Treatment Guided by Daxor's BVA-100 Lowers Hospital Length of Stay by 55%

Patients Receiving BVA Stayed 2.5 Fewer Days in Hospital Resulting in Reduced Costs of Care

Related Keywords

United States ,Washington ,America ,Johnl Jefferies ,Pjonathan Feldschuh ,Michael Feldschuh ,Heart Failure Society Of America ,University Of Tennessee Health Science Center ,Daxor Corporation ,Heart Failure Society ,Annual Scientific Meeting ,Tennessee Health Science Center ,Chief Scientific Officer ,Stay After Blood Volume Analysis ,Hospitalized Heart ,